Nashan D, Hüning S, Heppt M V, Brehmer A, Berking C
Hautklinik, Klinikum Dortmund gGmbH, Beurhausstr. 40, 44137, Dortmund, Deutschland.
Hautklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Universitätsklinikum Erlangen, Erlangen, Deutschland.
Hautarzt. 2020 Jun;71(6):463-475. doi: 10.1007/s00105-020-04619-x.
The S3 guideline "Actinic keratosis and squamous cell carcinoma of the skin" was published on 30 June 2019. Subsequently, publications, reviews and meta-analyses appeared with new questions regarding the comparability of study data and heterogeneity of the evaluations, which are caused, among other things, by divergent measurement parameters as well as insufficient consideration of pretreatments and combined treatments. This concise overview was written in the context of criticism and in view of necessary developments and research. Topics include epidemiology, pathogenesis, prevention, clinical presentation, therapy and BK5103. Therapy is divided into local destructive procedures and topical applications. Recommendations with quotation marks are based on the actual guideline. Corresponding evidence levels are given. For the implementation in daily routine basic data, side effects and features of therapeutic options are mentioned. The current developments and questions concerning actinic keratoses become clear.
S3指南“皮肤光化性角化病和鳞状细胞癌”于2019年6月30日发布。随后，出现了一些出版物、综述和荟萃分析，提出了有关研究数据可比性和评估异质性的新问题，这些问题是由多种因素造成的，包括不同的测量参数以及对预处理和联合治疗的考虑不足。本简要概述是在批评的背景下，并鉴于必要的发展和研究而撰写的。主题包括流行病学、发病机制、预防、临床表现、治疗和BK5103。治疗分为局部破坏程序和局部应用。带引号的建议基于实际指南。给出了相应的证据水平。为了在日常实践中实施，提到了基本数据、副作用和治疗选择的特点。关于光化性角化病的当前发展和问题变得清晰明了。
